This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Should You Invest in the SPDR S&P Biotech ETF (XBI)?
by Zacks Equity Research
Sector ETF report for XBI
Arcellx (ACLX) Up 5% on Partnership Expansion With Gilead
by Zacks Equity Research
Arcellx (ACLX) and Gilead (GILD) expand their existing collaboration in cancer treatment. This deal is expected to close by year-end.
BioCardia (BCDA) Soars 168% on FDA Nod to Heart Failure Study
by Zacks Equity Research
The FDA approves BioCardia's (BCDA) phase III study on its CardiAMP cell therapy to treat patients with ischemic heart failure.
Kodiak (KOD) Beats Q3 Earnings, Provides Pipeline Updates
by Zacks Equity Research
Kodiak (KOD) reports better-than-expected third-quarter 2023 results and provides updates regarding its pipeline development plans.
Aclaris (ACRS) Lead Drug Fails Rheumatoid Arthritis Study
by Zacks Equity Research
Aclaris (ACRS) decides to stop the development of its lead drug after top-line data from a mid-stage study did not achieve any study goals. Shares plunge 86% following the news.
Moleculin (MBRX) Up 7% on Upbeat Updates From Annamycin Studies
by Zacks Equity Research
Moleculin (MBRX) announces positive interim data from its early-mid-stage studies of Annamycin in blood and lung cancer indications, along with encouraging third-quarter results. The stock rises 7%.
Novavax (NVAX) Beats on Q3 Earnings & Sales, Cuts Sales View
by Zacks Equity Research
Novavax (NVAX) reports better-than-expected third-quarter results, with earnings and revenues beating estimates. It lowers product sales guidance for 2023.
Immunovant (IMVT) Q2 Earnings Top Estimates, Pipeline in Focus
by Zacks Equity Research
Immunovant (IMVT) reports better-than-expected fiscal second-quarter 2023 results. Pipeline development is on track, with several data readouts scheduled from both batoclimab and IMVT-1402 programs.
Intellia (NTLA) Beats on Q3 Earnings, Provides Pipeline Update
by Zacks Equity Research
Intellia (NTLA) reports mixed third-quarter 2023 results. Management provides developmental and regulatory updates on its key pipeline candidates.
Jazz (JAZZ) Lags Q3 Earnings, Beats Sales, Raises '23 View
by Zacks Equity Research
Jazz (JAZZ) reports mixed results in third-quarter 2023. However, shares rose 2.5% post the announcement, likely on the back of raised guidance for 2023.
FATE Q3 Earnings Beat on Lower Expenses, Revenues Fall Y/Y
by Zacks Equity Research
FATE reports better-than-expected third-quarter 2023 financial results, driven by lower operating expenses. The stock rises about 5% in the after-market hours.
Catalyst (CPRX) Q3 Earnings Miss, Sales Top, '23 View Up
by Zacks Equity Research
Catalyst (CPRX) reports mixed third-quarter results. Firdapse and Fycompa sales continue to boost revenues. Management raises 2023 financial guidance. The stock gains 6% in the after-market hours.
Esperion (ESPR) Q3 Earnings Beat, Stock Up on Strong Revenues
by Zacks Equity Research
Esperion's (ESPR) third-quarter earnings and revenues beat estimates on the back of better-than-expected collaboration revenues. The company reiterates its financial guidance for 2023.
Sage Therapeutics (SAGE) Q3 Earnings Lag Estimates, Down 5%
by Zacks Equity Research
Sage Therapeutics (SAGE) reports dismal third-quarter results. It intends to price the recently approved oral postpartum depression pill Zurzuvae at $15,900 for an entire 14-day treatment course.
Bayer's (BAYRY) Q3 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Bayer (BAYRY) reports weaker-than-expected third-quarter 2023 results. Management maintains its 2023 outlook.
Iovance's (IOVA) Meets Q3 Earnings, Lags Sales Estimates
by Zacks Equity Research
Iovance's (IOVA) third-quarter earnings meet estimates, but sales miss the same.
Perrigo (PRGO) Lags on Q3 Earnings & Sales, Lowers '23 View
by Zacks Equity Research
Perrigo (PRGO) reports dismal third-quarter 2023 results. Management lowers guidance for earnings and sales. Stock price drops 5% post the announcement.
Vertex (VRTX) Q3 Earnings Beat, Sales Miss, Raises '23 View
by Zacks Equity Research
Vertex's (VRTX) third-quarter results reflect a year-over-year increase in revenues. The company raises its net product sales guidance for 2023.
Editas (EDIT) Q3 Earnings & Revenues Beat, Pipeline in Focus
by Zacks Equity Research
Editas' (EDIT) third-quarter 2023 results reflect a year-over-year increase in revenues. The stock of the company rises 18%.
Ultragenyx (RARE) Q3 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Ultragenyx (RARE) reports weaker-than-expected third-quarter 2023 results, missing earnings and sales estimates. Management reiterates the 2023 financial outlook.
Acadia (ACAD) Q3 Earnings and Sales Beat Estimates, Stock Up
by Zacks Equity Research
Acadia (ACAD) reports better-than-expected third-quarter 2023 results as both earnings and sales beat estimates. The stock rises in after-market hours.
Pacira (PCRX) Q3 Earnings and Revenues Miss, '23 View Updated
by Zacks Equity Research
Pacira (PCRX) announces weaker-than-expected third-quarter 2023 results. The company streamlines its 2023 guidance for net Exparel sales.
Apellis (APLS) Q3 Loss Wider Than Expected, Syfovre Drives Sales
by Zacks Equity Research
Apellis' (APLS) third-quarter 2023 bottom line misses estimates, while the top line beats the same. Newly approved product, Syfovre, drives sales in the reported quarter.
Novo Nordisk (NVO) Q3 Earnings and Sales Beat, 2023 View Up
by Zacks Equity Research
Novo Nordisk (NVO) reports encouraging third-quarter results, beating both earnings and sales estimates, driven by strong sales of diabetes and obesity care products. Management raises 2023 guidance.
Apellis Pharmaceuticals, Inc. (APLS) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Apellis Pharmaceuticals, Inc. (APLS) delivered earnings and revenue surprises of -39.29% and 9.81%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?